Tyra Biosciences, Inc.TYRANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank33
3Y CAGR-35.9%
5Y CAGR-37.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-35.9%/yr
Annual compound
5Y CAGR
-37.6%/yr
Consistent
Percentile
P33
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| 2025 | 28.54% |
| 2024 | 28.09% |
| 2023 | 45.36% |
| 2022 | 108.41% |
| 2021 | 186.49% |
| 2020 | 302.40% |
| 2019 | 0.00% |